Pembrolizumab tunes up chemotherapy in cervical cancer
D Romero - Nature Reviews Clinical Oncology, 2021 - nature.com
D Romero
Nature Reviews Clinical Oncology, 2021•nature.comChemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, is
the standard-of-care first-line treatment for patients with recurrent or metastatic cervical
cancer. Now, data from the KEYNOTE-826 trial show improved survival when
pembrolizumab is added to these regimens.In this phase III trial, 617 patients were randomly
assigned (1: 1) to receive chemotherapy plus either pembrolizumab or placebo. The co-
primary end points were progression-free survival (PFS) and overall survival (OS).
the standard-of-care first-line treatment for patients with recurrent or metastatic cervical
cancer. Now, data from the KEYNOTE-826 trial show improved survival when
pembrolizumab is added to these regimens.In this phase III trial, 617 patients were randomly
assigned (1: 1) to receive chemotherapy plus either pembrolizumab or placebo. The co-
primary end points were progression-free survival (PFS) and overall survival (OS).
Chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, is the standard-of-care first-line treatment for patients with recurrent or metastatic cervical cancer. Now, data from the KEYNOTE-826 trial show improved survival when pembrolizumab is added to these regimens.
In this phase III trial, 617 patients were randomly assigned (1: 1) to receive chemotherapy plus either pembrolizumab or placebo. The co-primary end points were progression-free survival (PFS) and overall survival (OS).
nature.com